CG
NKTR icon

Cutler Group’s Nektar Therapeutics NKTR Stock Holding History

Cutler Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-133
Closed -$3K – 4934
2022
Q3 		$3K Sell
133
-187
-58% -$11.1K ﹤0.01% 3993
2022
Q2 		$8K Sell
320
-6,580
-95% -$415K ﹤0.01% 3382
2022
Q1 		$67K Buy
6,900
+6,847
+12,919% +$1.01M ﹤0.01% 2005
2021
Q4 		$1K Buy
+53
New +$11.5K ﹤0.01% 5071
2020
Q2 		– Sell
-393
Closed -$20K – 4706
2020
Q1 		$20K Buy
+393
New +$122K ﹤0.01% 2316
2018
Q4 		– Sell
-387
Closed -$16K – 4388
2018
Q3 		$16K Sell
387
-1,226
-76% -$1.05M ﹤0.01% 2385
2018
Q2 		$131K Buy
1,613
+1,306
+425% +$1.51M 0.01% 983
2018
Q1 		$1K Sell
307
-733
-70% -$944K ﹤0.01% 4101
2017
Q4 		$9K Buy
+1,040
New +$615K ﹤0.01% 3220
2017
Q3 		– Sell
-993
Closed -$19K – 6420
2017
Q2 		$19K Sell
993
-1,080
-52% -$312K ﹤0.01% 3462
2017
Q1 		$3K Buy
2,073
+886
+75% +$199K ﹤0.01% 5177
2016
Q4 		$12K Buy
+1,187
New +$241K ﹤0.01% 4003
2016
Q2 		– Sell
-807
Closed -$1K – 7065
2016
Q1 		$1K Buy
807
+94
+13% +$18.1K ﹤0.01% 6061
2015
Q4 		$3K Buy
+713
New +$147K ﹤0.01% 5327

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cutler Group's NKTR Position: Q1 2024 in Review

Cutler Group held its Nektar Therapeutics (NKTR) position steady in Q1 2024 at 193 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1873.

Cutler Group first reported a position in NKTR in Q4 2015 and has held it in 32 quarters since. The position peaked at $1.41M in Q1 2018. 124 funds tracked by Wall St. Rank hold NKTR as of Q1 2024.

  • Cutler Group held 193 shares of Nektar Therapeutics worth $2K as of Q1 2024.
  • Cutler Group left its Nektar Therapeutics share count unchanged in Q1 2024.
  • Nektar Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1873 holding.
  • Cutler Group first reported a position in Nektar Therapeutics in Q4 2015 and has held it in 32 quarters since.
  • Cutler Group's Nektar Therapeutics position peaked at $1.41M in Q1 2018.
  • 124 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.